2024年
- August 2, 2024
- Option Agreement for drug discovery of extracellular vesicles derived from airway epithelial cells
- July 31, 2024
- 1Q Consolidated Financial Results for the Fiscal Year Ending March 31, 2025 (September 31, 2024) - Supplementary Information
- July 31, 2024
- Summary of Consolidated Financial Results(For the first quarter ended June 30, 2024) [Japanese GAAP]
- May 21, 2024
- Notice of Dividends of Retained Earnings
- May 10, 2024
- Summary of Consolidated Financial Results(For fiscal year ended March 31, 2024) [Japanese GAAP]
- May 10, 2024
- Consolidated Financial Results for the Fiscal Year Ended March 31, 2024 (May 10 2024) - Supplementary Information
- April 15, 2024
- Starting Date of Operation at the New Head Office
- February 6, 2024
- Summary of Consolidated Financial Results(For third quarter ended December 31, 2023) [Japanese GAAP]
- 1